Maia Biotechnology Inc (MAIA) Stock Price, Quote & News

Company Profile

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Industry: Biotechnology

Sector: Healthcare

Phone: 312 416 8592

Website: maiabiotech.com

Address:

444 West Lake Street, Suite 1700, Chicago, United States

MoneyHelix May. 15 at 9:41 PM

$MAIA It's just a game of patience now. - Clinical sites are enrolling patients and accumulating data. - Phase 2B signals were outstanding and have a high probability of translating into widespread clinical benefits. - Small molecule manufacturing is way easier than manufacturing biologics, and cheaper. -Pan-cancer therapy potential with high synergistic effects with other immunotherapies. -All Phase 3 capital has been secured and accelerated approval is in sight. - No more dilution necessary until huge clinical milestones are met. - Massive partnership potential, buyout potential, and possible bidding war on the horizon. Load up and be patient 🥂

0 · Reply

Chemaster May. 15 at 7:46 PM

$MAIA Entry buy was 3.42$ ... as of few moments ago, 1.41$ which is .09$ less than smart money paid 33M for with zero warrants. Plus, they are looking to 3x to 4x before they even consider selling or trimming until then. Great stock and price!

1 · Reply

LabPsycho May. 15 at 5:15 PM

$MAIA @FetchDog Great set of posts / reasonable speculations. It does seem like some news should be coming based on the history pace of news and somewhat of a dryspell PR wise.

1 · Reply

claybridge May. 15 at 3:24 PM

$MAIA some notable NEW tute purchases from Q1...

0 · Reply

EdV3 May. 15 at 3:20 PM

$MAIA TY Clay, yes Solas Capital Management now in with 4.3m shares. They only have 22 positions as well.

0 · Reply

claybridge May. 15 at 3:13 PM

$MAIA Hot off the press...new buyer Solas Capital now owns 7.1% of the OS!!!

0 · Reply

claybridge May. 15 at 3:09 PM

$MAIA the company has stated that the April offering will "fully fund" their ph3 trial. Key word: FULLY. They just cancelled their remaining ATM too.

0 · Reply

FetchDog May. 15 at 3:07 PM

$MAIA Their Phase 3 Pivotal NCT06908304 trial for 3L NSCLC currently has a primary completion date of July 31, 2027. That suggests completion of enrollment by late 2026. 3L trials are significantly shorter and cheaper than 2L or 1L trials. That matches MAIA's limited financing. The fact that the last offering did not require warrants is also very positive. The possibility of infinite dillution typical of many biotechs is significantly reduced.

0 · Reply

FetchDog May. 15 at 2:48 PM

$MAIA Termination the ATM at the present time may have been done to counteract upcoming negative news (in the ER) showing increasing trial costs and cash burn. At any moment MAIA may announce details of the enrollment progress for their phase 3 NSCLC trial. I suspect that news will be good, showing nice progress, but one never knows. The next ER may provide some details. I’ve decided to start accumulating small amounts of MAIA while the news cycle is mostly negative or apathetic and the stock price is below the last offering price of $1.50. I expect the price to start rising sometime during 2026-H2 as MAIA starts a positive news cycle: significant progress on phase 3 enrollment, top line data, warrant execution, and final phase 3 data. I don't believe MAIA has sufficient funds to complete their phase 3 NSCLC trial, but I'm hoping they exercise outstanding warrants after top line data. That should provide a cash runway to final data for Phase 3 NSCLC without another offering.

0 · Reply

claybridge May. 14 at 9:51 PM

$MAIA they're terminating their ATM. Wonder what is cooking?

3 · Reply

MAIA Biotechnology secures funding for clinical trial of ateganosine

Apr 8, 2026, 9:00 AM EDT - 5 weeks ago

MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy

Mar 31, 2026, 9:15 AM EDT - 6 weeks ago

MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Mar 27, 2026, 8:00 AM EDT - 7 weeks ago

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

Mar 4, 2026, 4:00 PM EST - 2 months ago

MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock

2026-03-03T10:20:12.000Z - 2 months ago

MAIA Biotechnology 20M share Spot Secondary priced at $1.50

2026-03-02T22:06:56.000Z - 2 months ago

MAIA Biotechnology announces common stock offering, no amount given

Mar 2, 2026, 5:00 PM EST - 2 months ago

MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

2026-02-24T13:50:43.000Z - 2 months ago

MAIA Biotechnology published a 2026 Letter to Shareholders

Feb 24, 2026, 8:45 AM EST - 2 months ago

MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market

2026-01-20T15:25:23.000Z - 4 months ago

MAIA Biotechnology highlights milestones, catalysts for FY26

Jan 20, 2026, 10:15 AM EST - 4 months ago

MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum

2025-12-24T13:10:35.000Z - 5 months ago

MAIA Biotechnology directors participate in private placement financings

Dec 24, 2025, 8:01 AM EST - 5 months ago

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

2025-12-16T21:30:33.000Z - 5 months ago

MAIA Biotechnology to sell 1.233M shares at $1.22 in private placement

2025-12-16T21:21:06.000Z - 5 months ago

MAIA Biotechnology announces $1.51M private placement

Dec 16, 2025, 4:15 PM EST - 5 months ago

MAIA Biotechnology Announces $1.51 Million Private Placement

Dec 11, 2025, 1:00 PM EST - 5 months ago

MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates

2025-12-11T14:16:42.000Z - 5 months ago

MAIA Biotechnology doses first patient in Phase 3 trial of ateganosine in NSCLC

2025-12-11T13:30:33.000Z - 5 months ago

MAIA Biotechnology CEO, board members acquire company shares

Dec 10, 2025, 2:00 PM EST - 5 months ago

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach

2025-12-01T14:20:17.000Z - 5 months ago

MAIA Biotechnology announces open market purchases by CEO, directors

Dec 1, 2025, 9:17 AM EST - 5 months ago

MAIA Biotechnology Announces Open Market Purchases by CEO and Directors

2025-11-21T14:10:31.000Z - 6 months ago

MAIA Biotechnology highlights momentum of ateganosine clinical program

Nov 21, 2025, 9:01 AM EST - 6 months ago

MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

2025-11-20T13:55:24.000Z - 6 months ago

MAIA Biotechnology CEO presents at Smart Diaspora 2025

Oct 27, 2025, 10:45 AM EDT - 7 months ago

MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-10-23T12:40:52.000Z - 7 months ago

MAIA Biotechnology details 30-month patient survival in Phase 2 trial of NSCLC

Oct 23, 2025, 8:36 AM EDT - 7 months ago

MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

2025-10-13T20:30:15.000Z - 7 months ago

MAIA Biotechnology to sell 603,769 shares at $1.22 in private placement

Oct 13, 2025, 4:20 PM EDT - 7 months ago

MAIA Biotechnology Announces $736,600 Private Placement

2025-10-07T13:01:04.000Z - 7 months ago

MAIA Biotechnology to initiate digital asset treasury strategy

Oct 7, 2025, 8:47 AM EDT - 7 months ago

MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets

2025-09-29T20:40:19.000Z - 8 months ago

MAIA Biotechnology announces $2.25M private placement

Sep 29, 2025, 4:30 PM EDT - 8 months ago

MAIA Biotechnology Announces $2.25 Million Private Placement

2025-09-24T12:16:31.000Z - 8 months ago

MAIA Biotechnology awarded $2.3M grant by NIH for THIO-101

Sep 24, 2025, 8:01 AM EDT - 8 months ago

MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent

2025-09-11T13:40:52.000Z - 8 months ago

MAIA Biotechnology highlights efficacy data from THIO-101 Phase 2 trial

Sep 5, 2025, 9:03 AM EDT - 9 months ago

MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

2025-08-27T13:10:42.000Z - 9 months ago

MAIA Biotechnology announces publication of interim clinical data on THIO-101

Aug 27, 2025, 9:01 AM EDT - 9 months ago

MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells

Jul 28, 2025, 8:01 AM EDT - 10 months ago

MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer

Jul 17, 2025, 9:17 AM EDT - 10 months ago

MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy

Jul 9, 2025, 9:15 AM EDT - 11 months ago

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

Jul 1, 2025, 9:00 AM EDT - 11 months ago

MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

Jun 24, 2025, 8:15 AM EDT - 11 months ago

MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

Jun 18, 2025, 9:15 AM EDT - 11 months ago

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

Jun 10, 2025, 8:46 AM EDT - 1 year ago

MAIA Biotechnology to Present at BIO International Convention 2025

Jun 5, 2025, 11:10 AM EDT - 1 year ago

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

Jun 5, 2025, 8:04 AM EDT - 1 year ago

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer

May 27, 2025, 5:35 PM EDT - 1 year ago

CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000

May 27, 2025, 4:30 PM EDT - 1 year ago

MAIA Biotechnology Announces Private Placement of Approximately $669,500

May 15, 2025, 11:05 AM EDT - 1 year ago

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 14, 2025, 10:15 AM EDT - 1 year ago

MAIA Biotechnology Announces Director Participation in Recent Private Placement

May 5, 2025, 11:45 PM EDT - 1 year ago

CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement

May 5, 2025, 4:05 PM EDT - 1 year ago

MAIA Biotechnology Announces $1.08 Million Private Placement

Apr 1, 2025, 8:30 AM EDT - 1 year ago

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

Mar 25, 2025, 8:46 AM EDT - 1 year ago

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

Mar 20, 2025, 9:20 AM EDT - 1 year ago

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

Mar 19, 2025, 11:00 AM EDT - 1 year ago

MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO

Feb 27, 2025, 8:51 AM EST - 1 year ago

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

Feb 26, 2025, 8:47 AM EST - 1 year ago

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

Feb 24, 2025, 4:30 PM EST - 1 year ago

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

Feb 18, 2025, 3:44 PM EST - 1 year ago

MAIA Biotechnology Announces Private Placement of $2,715,000

Feb 4, 2025, 8:51 AM EST - 1 year ago

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

Jan 12, 2025, 6:00 PM EST - 1 year ago

MAIA Biotechnology Transcript: Biotech Showcase 2025 Investor Conference

Jan 10, 2025, 9:45 AM EST - 1 year ago

MAIA Biotechnology to Present at Biotech Showcase 2025

Dec 19, 2024, 8:47 AM EST - 1 year ago

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

Dec 16, 2024, 8:37 AM EST - 1 year ago

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

Dec 9, 2024, 6:00 PM EST - 1 year ago

MAIA Biotechnology Announces Private Placement of Approximately $950,000

Dec 3, 2024, 8:17 AM EST - 1 year ago

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

MoneyHelix May. 15 at 9:41 PM

0 · Reply

Chemaster May. 15 at 7:46 PM

1 · Reply

LabPsycho May. 15 at 5:15 PM

$MAIA @FetchDog Great set of posts / reasonable speculations. It does seem like some news should be coming based on the history pace of news and somewhat of a dryspell PR wise.

1 · Reply

claybridge May. 15 at 3:24 PM

$MAIA some notable NEW tute purchases from Q1...

0 · Reply

EdV3 May. 15 at 3:20 PM

$MAIA TY Clay, yes Solas Capital Management now in with 4.3m shares. They only have 22 positions as well.

0 · Reply

claybridge May. 15 at 3:13 PM

$MAIA Hot off the press...new buyer Solas Capital now owns 7.1% of the OS!!!

0 · Reply

claybridge May. 15 at 3:09 PM

$MAIA the company has stated that the April offering will "fully fund" their ph3 trial. Key word: FULLY. They just cancelled their remaining ATM too.

0 · Reply

FetchDog May. 15 at 3:07 PM

0 · Reply

FetchDog May. 15 at 2:48 PM

0 · Reply

claybridge May. 14 at 9:51 PM

$MAIA they're terminating their ATM. Wonder what is cooking?

3 · Reply

claybridge May. 13 at 3:32 PM

$MAIA selling in this range has been exhausted. A little volume and there is upside bias. Accum/Dist trending up on the lower timeframes and working up to higher timeframes. Barring negative news, higher prices are coming over the next days/weeks IMO.

0 · Reply

Daddy044 May. 13 at 2:22 AM

$MAIA BUY THE STOCK! Going higher. Enrollment wont be an issue

1 · Reply

aku78 May. 12 at 9:28 PM

$MAIA loser stock

2 · Reply

Chemaster May. 11 at 8:28 PM

$MAIA This is not what you asked for but I have a Chemistry / Biochemistry degree but lack expertise so asked four deep thought AI's to respond. Your thoughts on response especially the highlighted paragraph? Interesting take on the THIO-104 control arm. Investigator’s choice of single-agent chemo (vinorelbine, gemcitabine, or docetaxel — if not previously exposed) is actually pretty standard for global Phase 3 trials in this exact population: 3L+ advanced NSCLC after CPI + chemo failure. In that setting, true “standard of care” is fragmented. Many patients have already seen docetaxel or aren’t fit for combos. Ramucirumab + docetaxel is mostly a 2L option and isn’t uniformly available/reimbursed or suitable globally for heavily pre-treated pts. Using single-agent keeps the control clinically relevant, ethical, and feasible for regulators and sites. HIGHLIGHT **MAIA’s Phase 2 (similar 3L post-CPI/chemo pts) showed median OS ~17.8 months with ateganosine sequenced to cemiplimab — vs historical chemo benchmarks of ~5–6 months in comparable later-line data. That’s a large delta they’re powering for. Even if the control arm does a bit better than pure historical numbers, success isn’t trivial.** Your enrollment point is fair — open-label trials can face friction if investigators feel the control isn’t optimal for certain patients. But the design (1:1, up to ~300 pts, primary OS endpoint) was clearly discussed with regulators, and the Ph2 signal plus Fast Track status should help attract sites/patients who see the potential upside.

0 · Reply

Biotech_Pharma_Investor May. 11 at 5:48 PM

$MAIA I am bit skeptical about the control arm of their ph3 trial. "Active Comparator: Investigator's choice of single-agent chemotherapy (vinorelbine, gemcitabine, or docetaxel)" This lowers the bar for success. But could hinder enrolment (e.g. Ramucirumab plus docetaxel not allowed as an option)? Any oncologist here?

4 · Reply

claybridge May. 11 at 1:26 PM

$MAIA Q1 10-Q is out, 60.8M OS, $34.4M cash.

1 · Reply

Chemaster May. 8 at 12:08 AM

$MAIA is the stock for transferring money from the impatient to the patient.

2 · Reply

LabPsycho May. 7 at 7:54 PM

$MAIA Well...maybe it is time for Vlad to announce something else off the wall like - Hey everybody, we are now putting all our cash in GOLD...or INTC? (near their all time highs of course).

2 · Reply

LabPsycho May. 6 at 3:05 PM

$MAIA I am going to keep posting my idea on how to 5X THIO's potential market value until someone takes the baton and runs with it. My antibody ADC-THIO construct shown below based on my computational chemistry and molecular dynamic simulations, and the hypothesis / plausibility is supported by several peer reviewed articles and my own creative, scientifically sound input. In my earlier posts I also describe quick, easy, cost effective pilot studies one could do in a lab in one day to evaluate feasibility. Come on $REGN or $RHHBY - see the light.

1 · Reply

claybridge May. 6 at 2:58 PM

$MAIA back in this AM at $1.39 for another try. I show resistance at $1.43. Last close above was 3/25. LFG!

0 · Reply

LabPsycho May. 6 at 2:40 PM

$MAIA @ppl_first You are omitting the parts about starting Phase 3 dosing, Phase 2 dosing, and clinical sites enrolling now in USA.

0 · Reply

ppl_first May. 6 at 2:25 PM

$MAIA PR's are all about financing and paying themselves. Interesting science, weak timing and low market attention. Could randomly spike, but likely to sit in the portfolio like a pile of shit for 9 months.

1 · Reply

Market Cap	78.43M
Revenue (ttm)	0.00
Net Income (ttm)	-22.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	541,900
Avg Vol	718,824
Day's Range	N/A - N/A
Shares Out	60.80M
Stochastic %K	60%
Beta	0.21
Analysts	Sell
Price Target	$14.00